abcl-8k_20230221.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 21, 2023

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

British Columbia		001-39781		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

2215 Yukon Street

Vancouver, BC

V5Y 0A1

(Address of registrant’s principal executive office)

(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares	ABCL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On February 21, 2023, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the year ended December 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure

In connection with its earnings call on February 21, 2023, to discuss its results for the year ended December 31, 2022, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on February 21, 2023.
99.2						Corporate presentation.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 21, 2023	ABCELLERA BIOLOGICS INC.

	By:	/s/ Carl L. G. Hansen
		Carl L. G. Hansen, Ph.D.
		Chief Executive Officer and Director (Principal Executive Officer)

Exhibit 99.1

NEWS RELEASE

AbCellera Reports Full Year 2022 Business Results

02/21/2023

•	Total revenue of $485 million, compared to $375 million in FY 2021

•	Total cumulative partnered program starts of 101, with 23 new starts in the year

•	Net earnings of $0.56 per share on a basic and $0.50 on a diluted basis, compared to earnings of $0.56 (basic) and $0.48 (diluted) per share in 2021

VANCOUVER, British Columbia, February 21, 2023 -- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“In 2022 we demonstrated strong topline results and ongoing success in our partnering business. Even more significant is the progress we made in scaling and expanding the capabilities of our engine during the year,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We believe we are at an inflection point and expect to drive deeper value with partners and to prove our ability to consistently deliver clinical candidates for patients in need.”

FY 2022 Business Summary

•

Earned $485.4 million in total revenue.

•

Generated net income of $158.5 million, compared to net income of $153.5 million in 2021.

•

Reached a cumulative total of 174 programs under contract with 40 different partners.

•

Started discovery on 23 partnered programs, bringing the cumulative number of partnered program starts to 101.

•

Reporting the advancement of three additional molecules, taking the cumulative total to eight molecules in the clinic.

Key Business Metrics

	Year Ended December 31,				Change
Cumulative Metrics	2021		2022		%
Number of discovery partners		36		40		11	%
Programs under contract		156		174		12	%
Partnered program starts		78		101		29	%
Molecules in the clinic		5		8		60	%

AbCellera added 18 partnered programs in 2022 to reach a cumulative total of 174 programs under contract that are either completed, in progress, or under contract with 40 different partners as of December 31, 2022 (up 12% from 156 on December 31, 2021). AbCellera started discovery on 23 partnered programs in 2022 to reach a cumulative total of 101 partnered program starts (up 29% from 78 on December 31, 2021). AbCellera’s partners advanced an

additional three molecules into the clinic in 2022, bringing the cumulative total to eight molecules in the clinic.

Discussion of FY 2022 Financial Results

•

Revenue – Total revenue was $485.4 million, compared to $375.2 million in 2021. Royalties associated with bamlanivimab and bebtelovimab were $443.0 million. The partnership business generated research fees of $40.8 million, compared to $19.1 million in 2021. Milestone payments were $0.9 million and licensing revenue was $0.7 million.

•

Research & Development (R&D) Expenses – R&D expenses were $107.9 million, compared to $62.1 million in 2021, reflecting continuing investments in the capacity and capabilities of AbCellera’s engine for antibody discovery and development.

•

Sales & Marketing (S&M) Expenses – S&M expenses were $11.3 million, compared to $6.9 million in 2021. The increase reflects continued investments in business development.

•

General & Administrative (G&A) Expenses – G&A expenses were $55.5 million, compared to $41.8 million in 2021, with the increase driven by investments to support the growth of the company.

•

Net Earnings – Net earnings were $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis, compared to $153.5 million, or $0.56 per share on a basic and $0.48 diluted basis in 2021.

•

Liquidity – $886.5 million of cash, cash equivalents, and marketable securities.

Q4 Highlights and Financial Results

•

Started nine partner-initiated programs.

•

U.S. emergency use authorization (EUA) for bebtelovimab was suspended due to emergence of COVID-19 variants resistant to the treatment.

•

Added ten programs under contract with two new partners.

Revenue for the fourth quarter of 2022 was $21.5 million, representing 4% of the total for 2022. $9.5 million was generated in the quarter from royalties on net sales of bebtelovimab prior to the EUA suspension, and $11.4 million was generated from research fees, representing 2% and 28% of the respective totals for 2022.

Operating expenses totaled $59.3 million in the fourth quarter or 22% of the total for 2022 and include $1.6 million in royalty fees, 2% of the total for the year.

The net loss for the fourth quarter was $29.9 million, or ($0.10) per share on a basic and diluted basis.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug

developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in antibody drug development. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops.

Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our engine and our level of market penetration. The metric also relates to our opportunities to secure programs under contract.

Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover or deliver antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Partnered program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting potential for near-term payments. Cumulatively, partnered program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our

business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Source: AbCellera Biologics Inc.

Inquiries

Media: Jessica Yingling, Ph.D.; [email protected], +1(236) 521-6774
Business Development: Murray McCutcheon, Ph.D.; [email protected], +1(604) 559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; [email protected], +1(778) 729-9116

AbCellera Biologics Inc.

Consolidated Statements of Income and Comprehensive Income

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)

	Year Ended December 31,
	2020			2021			2022
Revenue:
Research fees	$	19,848		$	19,076		$	40,802
Licensing revenue		-			20,778			696
Milestone payments		15,000			8,000			900
Royalty revenue		198,307			327,349			443,026
Total revenue		233,155			375,203			485,424
Operating expenses:
Royalty fees		27,143			45,516			66,436
Research and development⁽¹⁾		29,393			62,062			107,879
Sales and marketing⁽¹⁾		3,842			6,913			11,270
General and administrative⁽¹⁾		11,910			41,848			55,485
Depreciation, amortization, and impairment		4,836			14,451			27,843
Total operating expenses		77,124			170,790			268,913
Income from operations		156,031			204,413			216,511
Other (income) expense
Interest (income)		(293	)		(3,330	)		(16,079	)
Interest and other		6,811			6,080			4,045
Grants and incentives		(8,320	)		(17,486	)		(10,554	)
Total other income		(1,802	)		(14,736	)		(22,588	)
Net earnings before income tax		157,833			219,149			239,099
Income tax expense		38,915			65,685			80,580
Net earnings	$	118,918		$	153,464		$	158,519
Foreign currency translation adjustment		-			280			(1,671	)
Comprehensive income	$	118,918		$	153,744		$	156,848

Net earnings per share attributable to common shareholders
Basic	$	0.53		$	0.56		$	0.56
Diluted	$	0.45		$	0.48		$	0.50
Weighted-average common shares outstanding
Basic		159,195,023			275,763,745			285,056,606
Diluted		263,129,765			318,294,236			314,827,255

(1) Exclusive of depreciation, amortization, and impairment

AbCellera Biologics Inc.

Consolidated Balance Sheet

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

	December 31, 2021		December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	476,142	$	386,535
Marketable securities		246,835		499,950
Total cash, cash equivalents, and marketable securities		722,977		886,485
Accounts and accrued receivable		160,576		38,593
Restricted cash		25,000		25,000
Other current assets		21,247		75,413
Total current assets		929,800		1,025,491
Long-term assets:
Property and equipment, net		111,616		217,255
Intangible assets, net		148,392		131,502
Goodwill		47,806		47,806
Investments in and loans to equity accounted investees		50,313		72,522
Other long-term assets		30,642		46,331
Total long-term assets		388,769		515,416
Total assets	$	1,318,569	$	1,540,907
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$	32,017	$	33,150
Current portion of contingent consideration payable		22,934		44,211
Income taxes payable		35,683		-
Accrued royalties payable		22,506		19,347
Deferred revenue		7,536		21,612
Total current liabilities		120,676		118,320
Long-term liabilities:
Operating lease liability		36,413		76,675
Deferred revenue		27,409		19,516
Deferred grant funding		33,349		40,801
Contingent consideration payable		35,886		16,054
Deferred tax liability		37,370		33,178
Other long-term liabilities		1,733		3,086
Total long-term liabilities		172,160		189,310
Total liabilities		292,836		307,630
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2021 and 2022: 283,257,104 and 286,851,595 shares issued and outstanding at December 31, 2021 and 2022 respectively		722,430		734,365
Additional paid-in capital		35,357		74,118
Accumulated other comprehensive income (loss)		280		(1,391	)
Accumulated earnings		267,666		426,185
Total shareholders' equity		1,025,733		1,233,277
Total liabilities and shareholders' equity	$	1,318,569	$	1,540,907
Subsequent event

AbCellera Biologics Inc.

Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars)

	December 31, 2020			December 31, 2021			December 31, 2022
Cash flows from operating activities:
Net earnings	$	118,918		$	153,464		$	158,519
Cash flows from operating activities:
Depreciation of property and equipment		2,317			4,403			8,953
Amortization and impairment of intangible assets		2,519			10,062			18,890
Amortization of operating lease right-of-use assets		435			2,785			5,259
Stock-based compensation		8,397			30,646			49,481
Deferred tax expense		2,098			(2,018	)		(2,114	)
Other		4,707			3,570			8,547
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable		(5,467	)		(37,386	)		(22,715	)
Accrued royalties receivable		(197,553	)		59,864			129,171
Income taxes payable		36,412			(13,530	)		(88,609	)
Accounts payable and accrued liabilities		6,601			1,400			1,066
Operating lease liabilities		(350	)		(778	)		(3,064	)
Deferred revenue		21,810			8,624			6,183
Accrued royalties payable		27,143			(4,637	)		(3,160	)
Deferred grant revenue		(6,763	)		30,718			9,264
Other operating assets and liabilities		1,466			(2,603	)		1,689
Net cash provided by operating activities		22,690			244,584			277,360
Cash flows from investing activities:
Purchases of property and equipment		(9,673	)		(58,452	)		(70,660	)
Purchase of intangible assets		(5,000	)		-			(2,000	)
Purchases of marketable securities		-			(274,710	)		(763,982	)
Proceeds from marketable securities		-			27,608			510,631
Receipt of grant funding		-			32,621			16,434
Acquisitions, net of cash acquired		(87,643	)		(11,457	)		-
Long-term investments and other		1,783			(17,534	)		(17,369	)
Investment in and loans to equity accounted investees		(19,247	)		(30,323	)		(25,679	)
Net cash used in investing activities		(119,780	)		(332,247	)		(352,625	)
Cash flows from financing activities:
Repayment of long-term debt and contingent consideration		(19,942	)		(4,373	)		(323	)
Proceeds from long-term debt and exercise of stock options		16,490			5,487			2,755
Proceeds from convertible debentures		89,990			-			-
Payment of liability for in-licensing agreement and other		(387	)		(5,000	)		(4,060	)
Net proceeds from issuance of common shares		522,840			-			-
Proceeds from issuance of preferred shares - series A1 and A2 financing		74,662			-			-
Net cash provided by (used in) financing activities		683,653			(3,886	)		(1,628	)
Effect of exchange rate changes on cash and cash equivalents		-			(1,425	)		(9,599	)
Increase (decrease) in cash and cash equivalents		586,563			(92,974	)		(86,492	)
Cash and cash equivalents and restricted cash, beginning of year		7,553			594,116			501,142
Cash and cash equivalents and restricted cash, end of year	$	594,116		$	501,142		$	414,650
Restricted cash included within other current and other long-term assets		-			-			3,115
Total cash, cash equivalents, and restricted cash shown on the balance sheets	$	594,116		$	501,142		$	411,535
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases in accounts payable		656			5,397			5,868
Right-of-use assets obtained in exchange for operating lease obligation		1,679			36,638			50,694
Purchase of intangible assets in exchange for in-licensing agreement payable		9,060			-			-

DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate,” “believe,” “estimate,” “predict,” “project,” “potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2

FULL YEAR 2022. BUSINESS UPDATE SUMMARY. 1 ENGINE $915M in total cash, cash equivalents & marketable securities 10 YEARS 174 cumulative program under contract 101 PROGRAMS 101 cumulative partnered programs started 8 molecules in the clinic FULL YEAR 2022 BUSINESS UPDATE 3

AbCellera is an antibody discovery engine that delivers optimal clinical candidates to the clinic – and to patients – with greater precision and speed. HYPOTHESIS Investments in technology can improve the productivity of drug development. Philosophy Long-term value creation begins with building a great company that can create multiple products. FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4

STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. STRATEGY #2 Build a large and diversified portfolio of stakes in future antibody therapeutics. FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5

STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. TECHNOLOGY INFRASTRUCTURE THE ENGINE EXPERTS from TARGET to PATIENTS DATA SCIENCE INTEGRATION 2x faster solve the unsolvable highest quality unprecedented scale FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6

Strategy # 2 Build a large, diverse portfolio of stakes in future antibody therapies. 7 Copyright © ABCELLERA FULL YEAR 2022 BUSINESS UPDATE Partner- initiated programs technology development Discovery programs co-development programs pre-partnered programs

FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA Partner-initiated programs Discovery programs target partner-initiated Deal terms upfronts and research fees clinical milestones single-digit royalties on net sales high volume. High diversification. High potential Roi.

PARTNER-INITIATED PROGRAMS Co-Development Programs TRAGET Partner-initiated DEAL TERMS Upfronts, clinical milestones, and royalty position PLUS option to co-invest in program development to maintain up to a 50% ownership position Low volume deals with optionality for concentrated positions. FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9

10 COPYRIGHT © ABCELLERA FULL YEAR 2022 BUSINESS UPDATE TECHNOLOGY DEVELOPMENT Pre-Partnered Programs T-Cell Engagers Platform 5 starts GPCRs & Ion Channels Platform 6 starts Pandemic Response Platform 1 start Technology-development efforts with potential to generate first-in-class, wholly-owned assets.

11 COPYRIGHT © ABCELLERA FULL YEAR 2022 BUSINESS UPDATE 2/3 TECHNOLOGY & COMPANY BUILDING PEOPLE & PLATFORM Team development Data science Translational science Manufacturing PRE-PARTNERED PROGRAMS GPCRs and ion channels T-cell engagers Pandemic response (COVID-19) 1/3 PARTNERING PARTNERED PROGRAMS Deal quality, not volume Deeper partnerships that get partners to the clinic Execute on and expand existing partnerships AbCellera’s Capital Allocation

ONE DECADE OF ENGINE BUILDING. Investments ˜ 500 employees across 4 countries and 3 continents 650K+ sq.ft. of facilities lab, office, & manufacturing spaces by 2024 $ 500M+ platform investments capitalization $ 800M+ in equity raised since 2012 $ 150M+ in government contracts and financing 30%+ held by employees & directors financials $ 900M+ in total cash, cash equivalents & marketable securities $400M+ in accumulated earnings since 2012 13 COPYRIGHT © ABCELLERA FULL YEAR 2022 BUSINESS UPDATE FINANCIALS

Copyright © abcellera Full year 2022 business update Financials 14 Strong portfolio growth. Total # of Programs under contract 174 Total # of Discovery partners 40 Cumulative # of Partnered program starts 110 100 90 80 70 60 50 40 30 20 10 0 2014 2015 2016 2017 2018 2019 2020 2021 2022 101 Without downstream participation + With downstream participation Cumulative # of Molecules in the clinic 8 7 6 5 4 3 2 1 0 2014 2015 2016 2017 2018 2019 2020 2021 2022 Not showing year end figures historical results are not necessarily indicative of future results.

Copyright © abcellera Full year 2022 business update Financials 15 Large diversified portfolio in next-gen antibody therapies. 57% oncology 55% human health (known) n=81 35% human health (TBD) n=52 148 Partner-Initiated Programs under contract with downstream participation are diversified across these therapeutic areas 10% animal health n=15 15% neurology 11% Immunology 5% ophthalmology 4% Infectious disease 2% dermatology 6% other 42% oncology T cell-engagers n=5 50% undisclosed GPCRs & ion channels n-6 100% human health n=12 8% infectious disease pandemic response n=1 12 Pre-Partnered Programs started across these therapeutic areas

16 copyright © abcellera Full year 2022 business update financials Portfolio includes diverse program types that capture value. Partner-Initiated discovery programs 69 starts 131 under contract co-development programs 6 starts 17 under contract technology development pre-partnered programs 12 starts 1 partnered with downstream participation.

Copyright © abcellera Full year 2022 business update Financials Deepening stakes evidenced by strong growth of royalty rates. royalty on net sales Includes range of royalty and royalty-equivalent rates in each contract, considering sales tiers and step-downs 5th /95th percentile interquartile range mean * showing partner initiated programs under contract with downstream participation and partnering out agreements signed in period 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 2015-2019 n=37* 2020-2022 n-112*

Now 8 molecules in the clinic. YEAR 2022 BUSINESS UPDATE FINANCIALS MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) TAK-320/DNL919 UNDISCLOSED NBL-012 NBL-015/FL-301 NEW NBL-020 IVX-01 Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 Phase 1 Phase 1 Phase 1 IND/CTA authorized Clinical field study infectious disease: COVID-19 infectious disease: COVID-19 neurology: Alzheimer’s Disease undisclosed dermatology gastrointestinal disease immunology oncology oncology animal health lilly denali undisclosed noyarock xinvetx Abcellera pre-partnered program partnered abcellera partner initiated discovery trianni license abcellera partner initiated discovery

19 Copyright © ABCELLERA full year 2022 Business update financials $485.4M total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $375.2M 2021 $485.4M $443.0M $40.8M 2022

20 Copyright © ABCELLERA full year 2022 Business update financials Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT $62.1M +$45.8M $107.9M 2022 SALES & MARKETING +$4.4M $6.9M $11.3M GENERAL & ADMIN +$13.6M $41.8M $55.5M 2021 2022 2021 2022 2021 2022

Net earnings of $158.5M: equivalent to $0.56 (basic) and $0.50 (diluted) per share. Earnings USD NET EARNINGS $153.5M 2021 $158.5M 2022 EARNINIGS PER SHARE: BASIC $0.56 2021 $0.56 2022 EARNINIGS PER SHARE:DILUTED $0.48 2021 $0.50 2022 FULL YEAR 2022 BUSINESS UPDATE FINANCIAL COPYRIGHT © ABCELLERA 21

22 COPYRIGHT © ABCELLERA FULL YEAR 2022 BUSINESS UPDATE FINANCIALS -900 million in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M Marketable Securities $476M Cash & Equivalents $25M* 31-Dec-21 $272M OPERATING $253M Marketable Securities (net) $99M Other ($353M) INVESTING ($2M) FINANCING ($10M) FX $915M $500M Marketable Securities $387M Cash & Equivalents $28M* 30-Dec-22 * Restricted cash (including restricted cash in other assets)